ALK inhibitors, resistance development, clinical trials.

about

ALK inhibitors, resistance development, clinical trials.

Item

http://www.wikidata.org/entity/Q55262467

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

ALK inhibitors, resistance development, clinical trials.

@en

ALK inhibitors, resistance development, clinical trials.

@nl

type

Item

label

ALK inhibitors, resistance development, clinical trials.

@en

ALK inhibitors, resistance development, clinical trials.

@nl

prefLabel

ALK inhibitors, resistance development, clinical trials.

@en

ALK inhibitors, resistance development, clinical trials.

@nl

P1476

ALK inhibitors, resistance development, clinical trials.

@en

P2093

J M Rothenstein

http://www.w3.org/2001/XMLSchema#string

N Chooback

http://www.w3.org/2001/XMLSchema#string

P2860

Crizotinib resistance: implications for therapeutic strategies

The ALK Inhibitor Ceritinib Overcomes Crizotinib Resistance in Non-Small Cell Lung Cancer

Discovery of Brigatinib (AP26113), a Phosphine Oxide-Containing, Potent, Orally Active Inhibitor of Anaplastic Lymphoma Kinase

Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer.

Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma.

Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.

Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis

Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer.

Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers.

CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1-2 study.

P304

S59-S67

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3747/CO.25.3760

http://www.w3.org/2001/XMLSchema#string

P433

Suppl 1

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-06-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29910648

http://www.w3.org/2001/XMLSchema#string

P932

6001759

http://www.w3.org/2001/XMLSchema#string